Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences Corp corporate vice president Daniel J. Lippis exercised employee stock options for 1,019 shares of common stock at an exercise price of $59.2567 per share, then sold 1,019 shares of common stock at a weighted average price of $85.3822.
These transactions were executed on March 11, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on July 30, 2025. Following the sale, Lippis directly holds 33,933.9103 shares of Edwards Lifesciences common stock, indicating he retained the vast majority of his equity position.
Edwards Lifesciences (EW) submitted a Form 144 notice relating to Common Stock with a broker identified as Charles Schwab & Co., Inc. The filing lists a transaction date of 03/11/2026 described as an Employee Stock Option Exercise with “Broker Payment for Cashless Exercise.” The filing also lists two prior entries under "Securities Sold During The Past 3 Months" for Daniel J. Lippis with dated entries 12/12/2025 and 01/09/2026 and amounts 85625.00 and 87332.00 respectively.
Edwards Lifesciences reported a Form 144 covering the proposed sale of 26,000 shares of Common Stock on 03/11/2026. The filing lists Employee Stock Option Exercise - Broker Payment for Cashless Exercise as the transaction method and identifies Charles Schwab & Co. as the broker.
Edwards Lifesciences executive Donald E. Bobo Jr., CVP, Strategy/Corporate Development, exercised employee stock options for 11,340 shares and on the same day sold 11,340 shares of common stock at a weighted average price of $85.9286, under a pre-established Rule 10b5-1 trading plan. After these transactions, he directly owned 21,266.2532 shares, with additional indirect holdings of 38,900.5862 shares through a 401(k) and 121,756 shares held by a trust.
Edwards Lifesciences Corp executive Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development, reported an open-market sale of 24,000 shares of common stock on February 25, 2026 at a weighted average price of $83.8365 per share. After this sale, he directly owned 21,266.2532 shares. Indirect holdings were updated to 38,900.5862 shares through a 401(k) plan and 121,756 shares held by a trust, reflecting a correction of 13,396 shares that were previously reported as directly held. The sale price reflects multiple trades executed between $83.66 and $83.96.
EW reported an insider sale notice for Common stock showing 24,000 shares listed to be sold on 02/25/2026 via Morgan Stanley Smith Barney LLC in connection with an exercise of options under a registered plan for cash.
The excerpt also lists prior sales by BOBO JR FAMILY TRUST on 12/10/2025 and 12/12/2025 with quantities 11,340, 5,900, and 5,486 respectively.
Edwards Lifesciences outlines its 2025 business, emphasizing leadership in structural heart therapies. Transcatheter Aortic Valve Replacement (TAVR) remains the core franchise, representing 74% of 2025 net sales, while Transcatheter Mitral and Tricuspid Therapies contributed 9% and Surgical Structural Heart valves 17%.
The company reports an aggregate market value of common stock held by non‑affiliates of $45,899,189,298 as of June 30, 2025, with 580.8 million shares outstanding as of January 31, 2026. Research and development spending rose about 2% and reached roughly 18% of 2025 sales, reflecting heavy investment in next‑generation TAVR, TMTT and surgical platforms.
Edwards generated 58% of net sales in the United States and 42% internationally, operates in about 100 countries, and employed roughly 16,000 people as of December 31, 2025. The filing details extensive risk factors, including innovation and clinical trial execution, manufacturing quality, competition from Medtronic and Abbott, reimbursement pressure, global regulatory change, cybersecurity, AI governance, and tax and compliance exposure.
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported a tax-related share disposition. On February 22, 2026, he transferred 432 shares of common stock at a price of $79.78 per share to cover tax withholding. After this transaction, he directly owns about 33,933.9103 shares.
Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported a Form 4 showing a tax-withholding disposition of 176 shares of common stock on February 22, 2026. The shares were disposed of at a reported price of $79.78 per share, and he now directly holds about 9,089.4805 shares.
Ullem Scott B. reported disposition transactions in a Form 4 filing for EW. The filing lists transactions totaling 199 shares at a weighted average price of $75.87 per share. Following the reported transactions, holdings were 39,699 shares.